Cassini A, Högberg LD, Plachouras D, et al; Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66. https://doi.org/10.1016/S1473-3099(18)30605-4 PMID:30409683 DOI: https://doi.org/10.1016/S1473-3099(18)30605-4

Fondazione House of Ambrosetti. Rapporto Meridiano Sanità 2017. Online: https://acadmin.ambrosetti.eu/dompdf/crea_wmark.php?doc=L2F0dGFjaG1lbnRzL3BkZi9yYXBwb3J0by1tczIwMTctMjAyMTA0MDIxMC5wZGY%3D&id=11962&muid=corporate (Accessed August 2022).

Antibacterial agents in clinical development - An analysis of the antibacterial clinical development pipeline. Online https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf (Accessed August 2022)

Istituto Superiore di Sanità. Antibiotico-resistenza. Aspetti epidemiologici in Italia. Online https://www.epicentro.iss.it/antibiotico-resistenza/epidemiologia-italia (Accessed August 2022)

Circolare Min. Sal. del 3/12/2019. Rapid Risk Assessment dell’ECDC: enterobatteri resistenti ai carbapenemi (CRE) 26 settembre 2019. Ten threats to global health in 2019. Online https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2019&codLeg=71976&parte=1%20&serie=null (Accessed August 2022)

Girometti N, Lewis RE, Giannella M, et al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore). 2014;93(17):298-309. https://doi.org/10.1097/MD.0000000000000111 PMID:25398065 DOI: https://doi.org/10.1097/MD.0000000000000111

De Angelis G, D’Inzeo T, Fiori B et al. Burden of Antibiotic Resistant Gram Negative Bacterial Infections: evidence and Limits. J Med Microbiol Diagn. 2014;3:1. Online https://www.hilarispublisher.com/open-access/burden-of-antibiotic-resistant-gram-negative-bacterial-infections-evidence-and-limits-2161-0703.1000132.pdf (Accessed August 2022)

Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis. 2020;70(9):1799-1808. https://doi.org/10.1093/cid/ciz530 PMID:31400759 DOI: https://doi.org/10.1093/cid/ciz530

CHEERS 2022 Checklist. Online https://www.equator-network.org/wp-content/uploads/2013/04/CHEERS-2022-checklist-1.pdf (Accessed August 2022)

Fattore G; AIES. Proposta di Linee-Guida per la valutazione economica degli interventi sanitari. PharmacoEcon Ital Res Artic. 2009;11(2):83-93. https://doi.org/10.1007/BF03320660 DOI: https://doi.org/10.1007/BF03320660

Mennini FS, Paoletti M, Bini C, Marcellusi A, Falcone M, Andreoni M. Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP). Glob Reg Health Technol Assess. 2022;9(1):45-57. https://doi.org/10.33393/grhta.2022.2287 PMID:36628307 DOI: https://doi.org/10.33393/grhta.2022.2287

Suetens C, Latour K, Kärki T, et al; Healthcare-Associated Infections Prevalence Study Group. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill. 2018;23(46):1800516. https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516 PMID:30458912 DOI: https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516

Sievert DM, Ricks P, Edwards JR, et al; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14. https://doi.org/10.1086/668770 PMID:23221186 DOI: https://doi.org/10.1086/668770

Zarb P, Coignard B, Griskeviciene J, et al; National Contact Points for the ECDC pilot point prevalence survey; Hospital Contact Points for the ECDC pilot point prevalence survey. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill. 2012;17(46):20316. https://doi.org/10.2807/ese.17.46.20316-en PMID:23171822 DOI: https://doi.org/10.2807/ese.17.46.20316-en

European Centre for Disease Prevention and Control. Point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals. 2013; Online https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf (Accessed August 2022)

ECDC. Antimicrobial resistance surveillance in Europe 2012. List of microorganism - pneumoniae. Online https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf (Accessed August 2022)

Malacarne P, Langer M, Nascimben E, et al; Italian Group for the Evaluation of Interventions in Intensive Care Medicine. Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9,493 patients from 71 Italian intensive care units. Crit Care Med. 2008;36(4):1105-1113. https://doi.org/10.1097/CCM.0b013e318169ed30 PMID:18379234 DOI: https://doi.org/10.1097/CCM.0b013e318169ed30

Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. World J Emerg Surg. 2012;7(1):36. https://doi.org/10.1186/1749-7922-7-36 PMID:23190741 DOI: https://doi.org/10.1186/1749-7922-7-36

Archivio Farmadati. Online https://gallery.farmadati.it

Lucioni, C., et al., I costi della sepsi in Italia. Farmeconomia e percorsi terapeutici, 2001. 2(3). https://doi.org/10.7175/fe.v2i3.727 DOI: https://doi.org/10.7175/fe.v2i3.727

Ministero dell’Economia e delle Finanze. Libro verde sulla spesa pubblica. Online https://www.mef.gov.it/ministero/commissioni/ctfp/documenti/Libro_verde_spesa_pubblica.pdf (Accessed August 2022)

Tariffario nazionale. Remunerazione delle prestazioni di assistenza specialistica ambulatoriale. 2013. Online https://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=28/01/2013&redaz=13A00528&artp=3&art=1&subart=1&subart1=10&vers=1&prog=001. (Accessed August 2022)

Simon MS, Sfeir MM, Calfee DP, Satlin MJ. Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia. Antimicrob Agents Chemother. 2019;63(12):e00897-e19. https://doi.org/10.1128/AAC.00897-19PMID:31548187 DOI: https://doi.org/10.1128/AAC.00897-19

Tariffario nazionale. Remunerazione delle prestazioni di assistenza ospedaliera. 2013. Online https://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=28/01/2013&redaz=13A00528&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001 (Accessed August 2022)

Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-Resistant EnterobacteriaceaeInfections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials. Open Forum Infect Dis. 2017;4(2):ofx063. https://doi.org/10.1093/ofid/ofx063PMID:28584849 DOI: https://doi.org/10.1093/ofid/ofx063

ISTAT. Tasso di occupazione. 2018. Online http://dati.istat.it/Index.aspx?DataSetCode=DCCV_TAXOCCU1 (Accessed August 2022)

Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for Methicillin-Resistant Staphylococcus aureus Prevention in Adult ICUs: A Cost-Effectiveness Analysis. Crit Care Med. 2017;45(8):1304-1310. https://doi.org/10.1097/CCM.0000000000002484 PMID:28471887 DOI: https://doi.org/10.1097/CCM.0000000000002484

Lee BY, Wiringa AE, Bailey RR, et al. The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2010;31(11):1130-1138. https://doi.org/10.1086/656591 PMID:20923285 DOI: https://doi.org/10.1086/656591

Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539-545. https://doi.org/10.1016/j.jval.2010.10.029 PMID:21669378 DOI: https://doi.org/10.1016/j.jval.2010.10.029

ISTAT. Tavole di mortalità. Online http://dati.istat.it/Index.aspx?DataSetCode=DCIS_MORTALITA1# (Accessed August 2022)

Righi E, Peri AM, Harris PN, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017 Mar 1;72(3):668-677. https://doi.org/10.1093/jac/dkw459 PMID:27999023 DOI: https://doi.org/10.1093/jac/dkw459

ISTAT. Indice dei prezzi al consumo per famiglie, operai ed impiegati. Online https://www.istat.it/it/archivio/30440

Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778-792. https://doi.org/10.1097/00005650-199806000-00002 PMID:9630120 DOI: https://doi.org/10.1097/00005650-199806000-00002

Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. https://doi.org/10.1093/cid/ciw353 PMID:27418577 DOI: https://doi.org/10.1093/cid/ciw353

Jim O’Neill. Wellcome Trust and UK Government. Tackling Drug-Resistant Infections Globally: final report and recommendations. The Review on Antimicrobial Resistance. May 2016; Online https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (Accessed August 2022)